Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12691903 | 0.83 | MAOB (0.33) | MAOB | |
| SCHEMBL10029425 | 0.81 | ATM (0.34) | ELANEMAOBNPSR1ALDH1A1CYP1A2 | |
| SCHEMBL12691975 | 0.76 | MAOB (0.31) | MAOBALDH1A1CYP1A2CYP2A6SLC6A2 | |
| SCHEMBL15255363 | 0.76 | ATM (0.35) | ELANEMAOBMAPTNPSR1ALDH1A1 | |
| SCHEMBL2233294 | 0.75 | KDM4E (0.30) | ALDH1A1 | |
| SCHEMBL21142321 | 0.73 | DPP4 (0.31) | — | |
| SCHEMBL10035307 | 0.71 | SLC6A2 (0.36) | MAOBMAPTNPSR1ALDH1A1CYP1A2 | |
| SCHEMBL14578492 | 0.71 | SLC6A2 (0.36) | MAOBMAPTNPSR1ALDH1A1CYP1A2 | |
| SCHEMBL18643566 | 0.71 | SLC6A2 (0.36) | MAOBMAPTNPSR1ALDH1A1CYP1A2 | |
| SCHEMBL19367692 | 0.71 | CYP1A2 (0.33) | MAOBNPSR1ALDH1A1CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158292-A1 | METHOD FOR PRODUCING METHIONINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
| US-20130150611-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130072713-A1 | METHOD FOR PRODUCING METHIONINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-03-21 | — | — | US | disclosed |
| US-8350051-B2 | Process for producing alpha-hydroxyketone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20110178309-A1 | PROCESS FOR PRODUCING ALPHA-HYDROXYKETONE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178309-A1 | PROCESS FOR PRODUCING ALPHA-HYDROXYKETONE COMPOUND | BCKDK, PDK4, HK1 | ELANE 4812/4885MAOB 1036/4885MAPT 3174/4885 |
| US-20130158292-A1 | METHOD FOR PRODUCING METHIONINE | MTR, MSMO1, MGMT | ELANE 1407/4885MAOB 67/4885MAPT 3552/4885 |
| US-20130072713-A1 | METHOD FOR PRODUCING METHIONINE | MTR, MGMT, BBOX1 | ELANE 1094/4885MAOB 101/4885MAPT 4015/4885 |
| US-20130150611-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER | ADH5, ADH1A, ADH1C | ELANE 2625/4885MAOB 291/4885MAPT 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.